Anti-KCNK9 (TASK-3) antibody, Mouse monoclonal
SIGMA/K0514 - clone KCN-75, purified from hybridoma cell culture
MDL Number: MFCD06798710
Product Type: Chemical
Immunohistochemistry
Analysis of KCNK9/TASK-3 in human cerebellum. (Panel A) Illustration at low magnification view of a 4 μm thick section. The Purkinje cells (P) as well as the molecular (m) and granule (g) layers show positive staining with Monoclonal Anti-KCNK9/TASK3 (Cat. No. K0514) at 5 μg/mL, whereas the white matter (w) demonstrates substantially weaker reaction. (Panel B) Higher magnification view of a different area; (Panels C and D) illustration of the strong positive staining of the Purkinje cells at high magnification.
Courtesy of Dr. Zoltan Rusznak, Medical School, University of Debrecen, Hungary.
Analysis of KCNK9/TASK-3 in human cerebellum. (Panel A) Illustration at low magnification view of a 4 μm thick section. The Purkinje cells (P) as well as the molecular (m) and granule (g) layers show positive staining with Monoclonal Anti-KCNK9/TASK3 (Cat. No. K0514) at 5 μg/mL, whereas the white matter (w) demonstrates substantially weaker reaction. (Panel B) Higher magnification view of a different area; (Panels C and D) illustration of the strong positive staining of the Purkinje cells at high magnification.
Courtesy of Dr. Zoltan Rusznak, Medical School, University of Debrecen, Hungary.
Western Blotting Whole extract of cultured T-47D cells (Human breast carcinoma) were separated on SDS-PAGE and probed with Anti-KCNK9 (TASK-3) antibody, Mouse monoclonal, Clone: KCN-75 (Cat. No. K0514). The antibody was developed using 1:2,500 Anti-Mouse IgG (Fab specific)-Peroxidase antibody produced in Goat (Cat. No. A2304). Lanes 1. 1:1,000 antibody 2. 1:2,000 antibody 3. Negative Control
| antibody form | purified from hybridoma cell culture |
| antibody product type | primary antibodies |
| biological source | mouse |
| clone | KCN-75, monoclonal |
| conjugate | unconjugated |
| form | buffered aqueous solution |
| isotype | IgG2b |
| mol wt | antigen ~40 kDa (representing the KCNK9 monomer, and a weaker band at 80 kDa representing the KCNK9 dimer) |
| shipped in | dry ice |
| species reactivity | human |
| storage temp. | −20°C |
| target post-translational modification | unmodified |
| technique(s) | immunocytochemistry: suitable |
| indirect ELISA: suitable | |
| microarray: suitable | |
| western blot: 4-8 μg/mL using whole extract of cultured T-47D cells (human breast carcinoma) | |
| UniProt accession no. | Q9NPC2   |
| Application: | Anti-KCNK9 (TASK-3) antibody, Mouse monoclonal has been used in: • immunoblotting • immunohistochemistry • immunocytochemistry |
| Biochem/physiol Actions: | Potassium two pore domain channel subfamily K member 9 (KCNK9) is expressed in carcinomas including breast, lung, colon as well as in metastatic prostate. In 10% of breast cancer patients this gene is amplified, and in 44% the protein is overexpressed. |
| Biochem/physiol Actions: | The gene KCNK9 (potassium two pore domain channel subfamily K member 9) encodes a tandem pore domain potassium channel that dimerizes to form a K+-selective pore. It is highly sensitive to change in pH and is involved in background leak potassium currents found in many cell types. The channel increases the hypoxia tolerance of malignantly transformed cells and facilitates its proliferation and/or survival. It may serve as a potential target for cancer therapies. Mutations in this gene can cause defects in the neuronal migration and have been associated with Birk Barel mental retardation dysmorphism syndrome. This oncogenic potassium channel is found to be expressed in epithelial ovarian cancer and patients with increased expression of this protein have better survival rates. |
| Disclaimer: | Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals. |
| General description: | Monoclonal Anti- KCNK9 (TASK-3), Clone KCN-75, (mouse IgG2b isotype) is derived from the KCN-75 hybridoma produced by the fusion of mouse myeloma cells (NS1) and splenocytes from BALB/c mice immunized with a synthetic peptide. Potassium two pore domain channel subfamily K member 9 (KCNK9) gene has been localized to the chromosomal region 8q24. |
| General description: | The gene KCNK9 (potassium two pore domain channel subfamily K member 9), also referred to as TWIK-related acid sensitive K(+) channel-3 (TASK-3), encodes a new member of the K2P (two pore domain K+ channel) family of proteins. It is found to be expressed in several rat tissues, such as brain, kidney, liver, lung, colon, stomach, spleen, testis, and skeletal muscle. It is also expressed to a lesser extent in heart and small intestine. All the potassium channels contain a conserved P domain that is involved in providing K+ selectivity and two, four, or six transmembrane segments. |
| Immunogen: | synthetic peptide corresponding to amino acids 360-374 in the C-terminus of human KCNK9. |
| Physical form: | Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide. |
| RIDADR | NONH for all modes of transport |
| WGK Germany | nwg |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Storage Temp. | −20°C |
| UNSPSC | 12352203 |